Pharmaceutical

Otsuka wins FDA breakthrough therapy designation for IgAN drug 

This positive news comes after Otsuka’s Phase III Alzheimer’s agitation trial failed to meet its primary endpoint, announced earlier this week.

Feb 16, 2024 - 18:00
Otsuka wins FDA breakthrough therapy designation for IgAN drug 
This positive news comes after Otsuka’s Phase III Alzheimer’s agitation trial failed to meet its primary endpoint, announced earlier this week.
Read the original article

Tags:

Previous Article

Sarepta’s Elevidys makes advances towards expanded DMD label

Next Article

QBiotics wins FDA orphan status for rainforest-derived cancer drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson agrees to acquire Ambrx Biopharma for...

Jan 9, 2024

STAT+: Burning questions for the 2024 JPM Healthcare Conference

STAT+: Burning questions for the 2024 JPM Healthcare Co...

Jan 4, 2024

Opinion: Biden’s budget boosts funds for future pandemics, but cuts them for current ones

Opinion: Biden’s budget boosts funds for future pandemi...

Mar 28, 2023